M&T Bank
NAVB

M&T Bank’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

M&T Bank’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-830
Closed -$31K – 2190
2014
Q4 		$31K Hold
830
– – ﹤0.01% 1966
2014
Q3 		$22K Buy
+830
New +$22K ﹤0.01% 2154

Other funds holding NAVB

PM
Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

M&T Bank's NAVB Position: Q1 2015 in Review

M&T Bank sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q1 2015, closing a stake of 830 shares — an estimated $31K sold.

M&T Bank first reported a position in NAVB in Q3 2014 and held it in 2 quarters. The position peaked at $31K in Q4 2014. 82 funds tracked by Wall St. Rank hold NAVB as of Q1 2015.

  • M&T Bank reported no remaining Navidea Biopharmaceuticals Inc. position as of Q1 2015 after selling out during the quarter.
  • M&T Bank sold 830 Navidea Biopharmaceuticals Inc. shares in Q1 2015, an estimated $31K.
  • M&T Bank first reported a position in Navidea Biopharmaceuticals Inc. in Q3 2014 and held it in 2 quarters.
  • M&T Bank's Navidea Biopharmaceuticals Inc. position peaked at $31K in Q4 2014.
  • 82 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q1 2015.

Based on M&T Bank's 13F filing for Q1 2015, filed 14 May 2015.